Precigen, Inc. (NASDAQ:PGEN) has been assigned an average “Buy” rating by the six analysts who currently cover the company, Marketbeat reports. Six analysts rated the stock with a buy rating. The 12-month average price target among brokers who have rated the stock over the past year is $11.25.
A number of analysts have published reports on the company. JMP Securities reaffirmed a “buy” rating and set a price target of $13.00 on Precigen shares in a report on Tuesday, December 14. Zacks Investment Research upgraded Precigen from a “hold” rating to a “buy” rating and set a price target of $3.50 for the company in a Tuesday, January 11 report.
Shares of PGEN traded down $0.02 in Friday’s midday session, hitting $2.19. 20,954 shares were traded, against an average volume of 1,822,476. Precigen has a 52-week low of $2.19 and a 52-week high of $9.84. The stock has a fifty-day simple moving average of $3.43 and a 200-day simple moving average of $4.60. The company has a market capitalization of $452.76 million, a P/E ratio of -3.77 and a beta of 2.27. The company has a debt ratio of 1.37, a quick ratio of 4.94 and a current ratio of 5.28.
Precigen Inc (NASDAQ:PGEN) last reported results on Monday, November 8. The biotech company reported ($0.15) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of ($0.14) by ($0.01). The company posted revenue of $21.56 million in the quarter, compared to $24.47 million expected by analysts. Precigen had a negative net margin of 109.91% and a negative return on equity of 68.90%. As a group, equity research analysts expect Precigen to post -0.49 EPS for the current fiscal year.
In other Precigen news, director Randal J. Kirk purchased 206,004 shares of the company in a transaction on Monday, November 22. The shares were purchased at an average price of $3.59 per share, for a total transaction of $739,554.36. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. Additionally, director Randal J. Kirk purchased 307,661 shares of the company in a transaction dated Friday, November 19. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $1,153,728.75. Disclosure of this purchase can be found here. In the past 90 days, insiders have bought 540,165 shares of the company worth $1,993,983 and sold 41,239 shares worth $149,183. Insiders hold 42.70% of the shares of the company.
Several large investors have recently changed their positions in the company. Miller Value Partners LLC increased its stake in Precigen by 1.7% in the second quarter. Miller Value Partners LLC now owns 9,257,868 shares of the biotech company valued at $60,362,000 after acquiring an additional 156,393 shares in the last quarter. Vanguard Group Inc. increased its equity stake in Precigen by 4.8% during Q2. Vanguard Group Inc. now owns 9,160,301 shares of the biotech company worth $59,726,000 after buying an additional 421,678 shares in the last quarter. Geode Capital Management LLC increased its equity stake in Precigen by 22.5% during the second quarter. Geode Capital Management LLC now owns 1,825,435 shares of the biotech company worth $11,901,000 after buying 334,776 additional shares in the last quarter. Morgan Stanley increased its equity stake in Precigen by 38.2% during Q2. Morgan Stanley now owns 1,222,855 shares of the biotech company worth $7,973,000 after buying an additional 338,055 shares in the last quarter. Finally, Invesco Ltd. increased its equity stake in Precigen by 27.2% during the 2nd quarter. Invesco Ltd. now owns 1,208,714 shares of the biotech company worth $7,880,000 after purchasing an additional 258,280 shares in the last quarter. 66.66% of the shares are currently held by institutional investors and hedge funds.
Precigen, Inc is a biotechnology company engaged in the research and development of synthetic biology technologies. The company focuses on programming biological systems to mitigate disease, address environmental issues, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics.
Feature Article: Fundamental Analysis – How It Helps Investors
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Precigen right now?
Before you consider Precigen, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes big…and Precigen wasn’t on the list.
While Precigen currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here